Everest Organics Limited has announced that Oseltamivir, API has been developed and manufactured in the plant of Everest Organics Limited located at Sangareddy District, Telangana. Oseltamivir is well known as key active ingredient in the prevention of influenza A and influenza B. Recently it has been discovered that Oseltamivir is also effective in fighting against Covid-19 virus, the ongoing world pandemic in co-administration with other supporting drugs.
"Oseltamivir drug falls in a medication class called neuraminidase inhibitors. It is the major ingredient in the blockbuster Tamiflu composition, which is an approved drug for the treatment of H1N1 and is more recently supposedly possible in treating Novel Corona treatment. Everest is proud to state that it has developed Oseltamivir API vide Non infringement route. Everest Organics Limited has an edge in supplying the bulk drug Oseltamivir to the formulators at shorter notice said, Dr. Srikakarlapudi Sirisha, Director of Everest Organics Limited.
Furthermore with strong R&D capabilities, the Company from time to time shall evaluate its range of product in anti-viral segment that shall enable to create substantial value for all the stakeholders.
Shares of EVEREST ORGANICS LTD. was last trading in BSE at Rs.91.55 as compared to the previous close of Rs. 87.65. The total number of shares traded during the day was 6280 in over 73 trades.
The stock hit an intraday high of Rs. 94.3 and intraday low of 85.35. The net turnover during the day was Rs. 565574.